Find Clinical Trials

Inclusion Criteria: 1. 5 to 17 years of age (inclusive) presenting to the ED with an asthma exacerbation. 2. Demonstrate moderate-severe asthma exacerbation at triage (i.e., receive an institutional asthma score equivalent to moderate-severe asthma exacerbation or a Pediatric Respiratory Assessment Measure (PRAM) score of 6 or above). Exclusion Criteria: 1. Prior participation in the study. 2. Use of BPAP at any time within approximately 12 hours for this acute asthma exacerbation, including in prehospital, ED, or inpatient settings, prior to randomization. 3. Receipt of continuous albuterol for over 150 minutes prior to being approached for consent. 4. If a blood gas is obtained, PaCO2 greater than 60 mmHg on the most recent blood gas prior to being approached for consent. Note: Blood gas values are not required for eligibility confirmation. 5. Anticipated immediate need (i.e., within approximately an hour after completion of first-line therapy) for invasive mechanical ventilation (e.g., endotracheal tube or laryngeal mask airway) or non-invasive mechanical ventilation (e.g., continuous positive airway pressure (CPAP) or BPAP), as determined by the treating physician. 6. Presence of a tracheostomy or a baseline requirement for noninvasive ventilation. 7. Wheezing due to non-asthma causes (e.g., foreign body, tracheomalacia, vocal cord dysfunction, pulmonary edema, uncorrected congenital heart disease, cystic fibrosis, or anaphylaxis). 8. Absolute or relative contraindication to BPAP, defined as any of the following: 1. Facial trauma within the area where the face mask would be applied for BPAP (excluding minor abrasion or cuts on forehead or skull). 2. Uncontrollable vomiting (i.e., \> 3 episodes within approximately 1 hour prior to being approached for consent). 3. Hypotension for age, defined as systolic blood pressure (SBP) less than 70 plus twice the patient's age in years (i.e., SBP \< 70 + \[2 x age in years\]). 4. Glasgow Coma Score of 8 or less. 5. Known or clinical suspicion for air leak syndrome (e.g., pneumothorax, pneumomediastinum, pneumopericardium, or subcutaneous emphysema). 9. Weight \< 20 kg. 10. Presence of an intra-abdominal mass compressing the stomach (e.g., due to tumor or large volume ascites) through EMR or medical history. 11. Known or suspected pregnancy by history or if pregnancy test completed by clinical team. 12. Any medical condition that, in the opinion of a site investigator, could 1) lead to difficulty complying with protocol procedures, 2) interfere with the safe completion of the study, or 3) affect the validity of the endpoint assessments. 13. PRAM score less than 7 or greater than 10 based on concurrent clinical assessment by a healthcare provider after completion of standard first-line therapies, which is defined as receiving all of the following prior to ED arrival or during the ED encounter for this acute asthma exacerbation: 1. Albuterol with or without ipratropium bromide, either at least 3 albuterol doses via inhalation method (e.g., metered-dose inhaler (MDI) or nebulized) or at least one hour of continuous albuterol (i.e., continuous nebulized albuterol or three consecutive intermittent nebulized albuterol treatments as bridging therapy). 2. Corticosteroids (e.g., Prednisolone, Prednisone, Dexamethasone/Decadron, or Methylprednisolone) via enteral, intravenous, or intramuscular methods. Note: Oxygen is not a required first-line therapy. 14. Do not require continuous albuterol or a second round of albuterol treatments (e.g., three back-to-back treatments or one hour of burst albuterol treatment) following completion of standard first-line therapies.

Inclusion Criteria: * Provision of signed and dated informed consent form * Age ≥18 years * A history of physician-diagnosed persistent asthma or symptoms consistent with persistent asthma based on national or international guidelines for diagnosis and management of asthma. * Current use of controller therapy such as inhaled corticosteroid (ICS) or ICS in combination with long-acting beta agonist (LABA) * Asthma exacerbation requiring systemic corticosteroid therapy in the past 12 months * Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy or who have been amenorrheic for 12 months or more. * Asthma Impairment and Risk Questionnaire (AIRQ) Score \>2 Exclusion Criteria: * Clinical contraindications: 1. Physician diagnosis of other chronic pulmonary disease including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema or congenital disorders of the lungs or airways. 2. History of undergoing bronchial thermoplasty. 3. Intubation for asthma in the last 12 months 4. History of malignancy except non-melanoma skin cancer within the last five years. 5. Any chronic medical condition considered by the PI as a contraindication to inclusion in the study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, history of chronic or recurrent infections or immunodeficiency. 6. Mental illness or history of substance abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements. 7. History of smoking: i. Smoking \>1 time per week in the past year; ii. If ≥40 years old: Smoked ≥15 pack years; iii. If \<40 years old: Smoked ≥10 pack years; iv. Smoking equivalents of 1 pack cigarettes a day for 1 year: 1 cigar or pipe daily for 1 year; Hookah - 1 session per day for 1 year; E-cigarettes or vapes - 1 cartridge/tank/pod per day for 1 year; and active use of smoking/vaping marijuana, specified as once per week in the last year. 8. Allergy/sensitivity to study drugs or their formulations, including latex 9. Unwillingness to use reliable contraception if sexually active (IUD, birth control pills/patch, condoms). 10. Current participation in an interventional trial in which study administration was administered within the past 60 days or within 5 half-lives of the drug (whichever is greater) * Pregnancy, plans to get pregnant or nursing a baby. Female volunteers will be asked to use effective birth control (stable regimen of hormonal contraceptive use for at least 6 months, intrauterine device placement, or tubal ligation for at least 6 months through at least one week after study completion) and will provide a urine sample to test for pregnancy on study days. If the test is positive or the participant has reason to believe she may be pregnant, she will be dismissed from the study. Women who have been amenorrheic for 12 months may participate. Male volunteers will be asked to use condoms for the duration of the study through at least one week after study completion. * Usage of the following medications: 1. Use of daily systemic corticosteroid therapy for asthma control 2. Use of any immunomodulatory therapy within the preceding 12 months, including biologics that are approved for asthma. 3. Currently receiving allergen immunotherapy 4. Use of any immunosuppressant therapy within the preceding 12 months will be reviewed by the study physician. * Laboratory: Participants who meet the following criteria will be excluded from study: 1. Positive QuantiFERON-tuberculosis (TB) gold assay. Cases of indeterminate QuantiFERON-TB test results will require a second specimen to be drawn. 2. Baseline absolute neutrophil count (ANC) \<1.0 x 109/L for participants of African descent, \<1.5 x 109/L for other participants * Allergy/sensitivity to study drugs or their formulations, including latex. * History of anaphylaxis requiring epinephrine treatment * Inability or unwillingness of a participant to give written informed consent. * Inability or unwillingness to self-administer injectable medication (anakinra or placebo).

Inclusion Criteria: * The patient is diagnosed with Type 2 Diabetes Mellitus according to the ADA 2024 criteria (Fasting Glucose ≥ 126 mg/dl, or Glucose after 2 hours of an Oral Glucose Tolerance Test ≥ 200 mg/dl, or HbA1C ≥ 6.5%, or with typical symptoms accompanied by any Glucose ≥ 200 mg/dl). * The duration of Type 2 Diabetes Mellitus does not exceed 10 years. * Classification by age of onset: Early onset group (\< 40 years) and typical onset group (≥ 40 years). * At least 6 months without the need for insulin and no recorded episodes of diabetic ketoacidosis since the time of diagnosis. * For the early-onset group: Autoantibodies (Anti-GAD, ICA) are negative and fasting C-peptide levels are \> 0.6 nmol/L. * The patient consents to participate in the study and signs the informed consent document. Exclusion Criteria: * Pregnant women or patients with acute illnesses at the time of assessment. * The patient has been diagnosed with or exhibits characteristics suggestive of Type 1 Diabetes Mellitus (such as a history of ketoacidosis, C-peptide \< 0.2 nmol/L). * Secondary diabetes mellitus due to pancreatic disorders (pancreatitis, pancreatic tumors, pancreatic resection), due to medications (glucocorticoids), or due to other endocrine disorders (Cushing's syndrome, hyperthyroidism, acromegaly). * Severe renal failure with an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m². * Use of medications that affect beta cell function or complications such as prolonged high-dose corticosteroids, immunosuppressive agents, or chemotherapy. * Not of Vietnamese ethnicity. * Non-compliance with treatment guidelines or failure to attend scheduled follow-up appointments.

Inclusion Criteria: * Diagnosis of stage 1 and 2 hypertension * Regular treatment for more than 6 months * There have been no changes in medication doses over the last three months. Exclusion Criteria: * Autoimmune and infectious diseases, diabetes * Chronic kidney disease, liver disease, cancer and AIDS * Pregnant women * Use of catabolic drugs or antibiotics * Use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotic * Habitual intake of royal jelly and propolis

Inclusion Criteria: * Female patients ≥18 years * Patients undergoing unilateral or bilateral therapeutic mastectomy for breast cancer * Patients undergoing pre-pectoral implant-based breast reconstruction, either: * One-stage DTI, or * Two-stage TE-I * Use of implant with or without biological or synthetic mesh * Contralateral prophylactic mastectomy allowed if a therapeutic mastectomy was performed on one side Exclusion Criteria: * Male patients * Subpectoral implant-based reconstruction * Autologous breast reconstruction * Delayed reconstructions not performed at the time of mastectomy * Incomplete clinical or follow-up data for primary endpoint analysis

Inclusion Criteria: 1. Participants aged 18-75 years old (inclusive), any gender; 2. Patients diagnosed with WHO Group 1 pulmonary arterial hypertension (PAH) via right heart catheterization (RHC) before dosing (see Appendix 1), including the following subtypes: * Idiopathic PAH; * Heritable PAH; * Drug- or toxin-induced PAH; * Inactive, connective tissue disease-associated PAH; * Simple congenital heart disease with left-to-right shunt-related PAH, at least 1 year post-repair surgery; 3. Symptomatic pulmonary arterial hypertension, WHO functional class II or III ; 4. Must also meet the following hemodynamic criteria: * Mean pulmonary arterial pressure (mPAP) at rest ≥25 mmHg; * Pulmonary arterial wedge pressure (PAWP) ≤15 mmHg; 5. Pulmonary vascular resistance (PVR) measured by RHC within 10 days before initial dosing ≥5 Wood Units (400 dyn·sec·cm-5), prior RHC results before screening are acceptable if they meet study requirements; 6. Receiving stable doses of background PAH therapy (i.e., for at least 90 days before first dosing, individualized target doses for each therapy reached and stable); for subcutaneous prostacyclin users, a 10% variation around the optimal dose is allowed following medical practice, detailed as follows: * Background PAH therapy refers to approved PAH-specific drugs, including ERA and/or PDE-5i or sGC stimulators and/or prostacyclin analogs or receptor agonists (subcutaneous). Note: PAH background therapy drugs should meet the following doses: Macitentan 10 mg qd, Ambrisentan 10 mg qd; Sildenafil ≥20 mg tid, Tadalafil 20-40 mg qd; Riociguat 2 mg or 2.5 mg tid; Selexipag 0.8-1.6 mg bid; Subcutaneous treprostinil ≥20 ng/kg/min. Note: Drugs used for acute pulmonary vasoreactivity testing are not considered background therapy. 7. During screening and within 10 days before first dosing, the mean of two 6-minute walk distance (6MWD) tests should be ≥150m and ≤450m, with a maximum difference of 15% (based on the higher value); the two tests should be at least 4 hours apart and no longer than 1 week apart (if the difference exceeds 15%, repeat once within 4 hours to 1 week). 8. Female participants of childbearing potential must have a negative serum pregnancy test before dosing, agree to regular urine or serum pregnancy tests during treatment (any one), use highly effective contraception before dosing, during treatment (including dosing interruption) and for 16 weeks (112 days) after the last dose, and avoid blood or egg donation for 16 weeks (112 days) after the last dose. 9. Male participants agree to use condoms, defined as using latex condoms or non-latex condoms made from non-natural (animal) membranes (e.g., polyurethane) during sexual activity with pregnant women or women of childbearing potential during the dosing period (including any interruption) and for 16 weeks (112 days) after the last dose, even if they have successfully undergone a vasectomy, and to avoid donating sperm during this time; 10. Participants understand and follow the study procedures, voluntarily participate, and sign the informed consent form. Exclusion Criteria: 1\) Diagnosed with WHO Group 2, 3, 4, or 5 pulmonary hypertension. 2) Diagnosed with the following PAH subtypes in WHO Group 1: * HIV-associated PAH * Portal hypertension-associated PAH * Schistosomiasis-associated PAH * PAH associated with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis * PAH patients with known positive acute pulmonary vasoreactivity test 3) History of echocardiogram within 6 months before screening showing left ventricular ejection fraction \<45%, or pre-dose echocardiogram showing left ventricular ejection fraction \<45%, or as assessed by the investigator, acute decompensated heart failure occurring within 30 days before screening, or evidence or history of clinically significant heart disease (including but not limited to: significant (≥2+) mitral or aortic valve regurgitation, restrictive or congestive cardiomyopathy, or pericardial constriction). 4\) Poorly controlled hypertension at rest during the screening period: seated systolic BP \>160 mmHg or seated diastolic BP \>100 mmHg, or pre-dose systolic BP \<90 mmHg on Day 1. 5\) Pre-dose ECG Fridericia corrected QT interval (QTcF) ≥470 ms for men, ≥480 ms for women, or personal/family history of long QT syndrome (LQTS) or sudden cardiac death. 6\) Any symptomatic coronary artery disease event (previous myocardial infarction, PCI, CABG, or angina), or history of cerebrovascular accident within 3 months before screening. Note: if coronary angiography shows no obstruction (lumen stenosis ≤50%), angina may not be an exclusion. 7\) Use of IV positive inotropic agents (such as dobutamine, dopamine, norepinephrine, vasopressin, milrinone, levosimendan, etc.) within 30 days before the screening visit. 8\) History of arterial or deep vein thrombosis within 6 months before dosing, or any spontaneous bleeding of any severity within 2 months before dosing. 9\) Untreated mild or more severe obstructive sleep apnea history. 10）Previous or planned heart or lung transplant, or expected lifespan \<12 months as assessed by the investigator. 11\) Diagnosed with chronic obstructive pulmonary disease (COPD) or other clinically significant lung diseases. 12\) Exclusion if there is evidence of interstitial lung disease (ILD) from a chest CT within 1 year before screening or a lung function test (PET) within 6 months before screening; if these test results are not available, or if the chest CT within 1 year shows mild or more severe ILD, a lung function test (PET) or chest CT must be done during the screening period, and patients with ILD detected are excluded. 13\) Before administration, hemoglobin (Hb) \> the upper limit of normal (ULN) for their gender or \<90 g/L, platelet count ≤100×10⁹/L, neutrophils \<1.5×10⁹/L, AST or ALT \>3×ULN, total bilirubin \>1.5×ULN, estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² (defined according to CKD-EPI 2021 formula). 14\) History of portal hypertension or chronic liver disease, including positive Hepatitis B surface antigen (HBsAg) and/or positive Hepatitis B core antibody (HBcAb) with HBV-DNA levels above the normal range; positive Hepatitis C virus (HCV) and positive HCV-RNA; positive HIV serology; positive Treponema pallidum antibody (TP-Ab) (if Treponema pallidum serology is positive, a non-Treponema pallidum serology test should be done, and if negative and judged by the investigator as a cured past syphilis infection, the patient can be included). 15\) Currently participating in other clinical studies; or has participated in a medical device or drug clinical study within 30 days before screening (except those who only signed the ICF but did not receive investigational drug or device intervention), or still within 5 half-lives (t1/2) of an investigational product (whichever is longer). 16\) Previously received treatment targeting the TGF-β superfamily (e.g., Sotatercept), including participation in clinical trials. 17\) Known allergies to large molecule protein products/monoclonal antibodies, the study drug or its excipients, or drugs of the same type. 18\) Started a cardiopulmonary rehabilitation exercise program within 90 days before screening, or planning to start one during the study (participants who have maintained a stable program and will continue during the study are eligible). 19\) History of opportunistic infections (e.g., invasive candidiasis or Pneumocystis pneumonia within 6 months before dosing); severe local infections (e.g., cellulitis, abscess) or systemic infections (e.g., sepsis) within 4 weeks before screening. 20\) Major surgery within 8 weeks before the first dose, or participants not fully recovered from previous surgery before the first dose. 21\) If receiving corticosteroid therapy, any of the following within 30 days before the first dose: taken \>20

Inclusion Criteria: * Women aged 18 years and older * Able to speak and understand Turkish * Diagnosed with preterm premature rupture of membranes (PPROM) * Gestational age between 28+0 and 35+5 weeks * Score of ≥1 on the Subjective Units of Disturbance Scale (SUDS) * Singleton pregnancy * Able and willing to communicate and participate in the study Exclusion Criteria: * Pregnancy achieved via assisted reproductive technologies * Presence of any obstetric complication other than PPROM * Presence of major fetal anomalies * Active labor at the time of recruitment * Hearing impairment * Presence of infection, wounds, or scars at tapping sites (for EFT application) * History of severe psychiatric disorder or currently receiving psychiatric treatment * Any maternal or fetal condition requiring emergency medical intervention

Inclusion Criteria: * Patient ≥ 18 years old, hospitalized at the USP - HUS * Estimated life expectancy ≥ 1 month (Pronopall score based on clinical data). * Montreal Cognitive Assessment (MoCA) scale score ≥ 26. * Able to understand the objective and risks of the study * VRISE score ≤ 25 after the VR familiarization procedure * Affiliation with the Social Security system or beneficiary of such social protection. * Signed consent from, able to understand and complete the questionnaires in French. Exclusion Criteria: * Patients with psychiatric disease * Patients under court protection * Uncontrolled epilepsy * Visual impairments (lack of binocular vision, blindness) and/or hearing impairments (deafness) preventing the use of virtual reality

Inclusion Criteria: * Female patients aged 18 to 70 years * Scheduled for elective breast cancer surgery * American Society of Anesthesiologists (ASA) physical status I to III * Able to understand and complete the Pittsburgh Sleep Quality Index (PSQI) * Willing to participate in the study * Provided written informed consent Exclusion Criteria: * Active infection * History of chronic inflammatory disease or autoimmune disease * Use of steroids or immunosuppressive drugs within the past 6 months * Known diagnosis of obstructive sleep apnea syndrome * Severe cognitive impairment preventing completion of the questionnaire * Planned emergency surgery * Refusal to participate or failure to provide informed consent

Inclusion Criteria: * Healthy Adults between the ages of 19 to 80 (12 of each biological sex assigned at birth). Exclusion Criteria: 1. Current smoker (within six months before screening; potential to confound exposure effects). 2. History or current diagnosis of any respiratory conditions (including, but not limited to asthma or chronic obstructive pulmonary disease (COPD), asthma/COPD overlap) or other medical conditions that the study physician determines may impact participant safety. 3. Any comorbidities or other concerns identified by the study physician which may impact study participation. 4. For participants of child-bearing potential: Current pregnancy, or plans to become pregnant during study enrolment.

Inclusion Criteria: * Adults with metastatic or locally advanced, unresectable solid tumors that have progressed on or after at least one available therapy. * Presence of one or more documented activating PIK3CA mutation in tumor tissue and/or blood. * At least 1 measurable lesion or evaluable disease per RECIST v1.1. * An ECOG performance status of 0 or 1. * Adequate organ function Exclusion Criteria: * Diabetes mellitus requiring anti-hyperglycemic medication. * Prior treatment with PI3Kα inhibitors * Symptomatic, untreated, or uncontrolled central nervous system metastases. * Receipt of any local or systemic anticancer therapy or investigational anticancer agent within a protocol-defined washout period prior to study treatment. * Unresolved clinically significant toxicities from prior anticancer therapy * History of a another malignancy within 2 years prior to screening (exception adequately treated cancers).

Inclusion Criteria: * 18 years old or older * Pregnant (or recently have given birth) at any gestational age * Must have experienced at least one adverse pregnancy outcome * Admitted for an extended inpatient stay * English speaking Exclusion Criteria: * Under 18 years old * Not currently pregnant or past one year postpartum * Not experienced at least one adverse pregnancy outcome * Not admitted for an extended inpatient stay at RMT

Main Inclusion Criteria: * Participants who have a documented history of physician-diagnosed asthma * Participants who have been using a stable and regular inhaled corticosteroid plus one additional asthma controller medication. * Participants must have a Childhood Asthma Control Test score ≥ 19. * Participants must have a pre-bronchodilator FEV1 ≤ 95% of predicted normal value. * Body mass index (BMI) ≤ 95 percentile for age and body weight of ≥ 14 kg or higher. * Female participants who experience menarche must have a negative urine pregnancy test. * Received no asthma medication other than run-in BFF MDI BID and albuterol/salbutamol as needed. Main Exclusion Criteria: * Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s). * Historical or current evidence of a clinically significant disease including, but not limited to cardiovascular, hepatic, renal, hematological, neurological, endocrine, gastrointestinal, or pulmonary. * Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, vital signs, or ECG. * Hospitalization for asthma * Narrow-angle glaucoma not adequately treated and/or change in vision, bladder dysfunction, bladder outlet obstruction/urinary retention or any other conditions where anticholinergic treatment is contraindicated and may be relevant. * Use of Long-acting muscarinic antagonist (LAMA), either alone or as part of an inhaled combination therapy. * Current use of any systemic beta-blockers. * Respiratory infection involving antibiotic treatment. * Systemic corticosteroid use for any reason (including asthma exacerbations). * Participants with a known hypersensitivity to beta 2-agonists, corticosteroids, anticholinergics, or any component of the MDI. * Participants who are medically unable to withhold their short-acting bronchodilators and other asthma medications. * Any use of marketed (eg, omalizumab, mepolizumab, benralizumab, reslizumab) or investigational biologic. * Regular use of a nebulizer or a home nebulizer for receiving asthma medications. * Use of any immunomodulators or immunosuppressive medication.

Inclusion Criteria: * Histologically confirmed diagnosis of HR+/HER2- breast cancer. * Documented evidence of advanced or recurrent disease that is not amenable to surgery/radiation for curative intent. * Participant has received at least one prior systemic therapy. * At least 1 measurable or evaluable target lesion according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening. * Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods. Exclusion Criteria: * Participants with triple-negative breast cancer. * Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. * Active malignancy (except for breast cancer, definitively treated in-situ carcinomas \[e.g., breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible. * Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment. * Significant cardiovascular impairment. * Active, uncontrolled infection. * Concurrent participation in another therapeutic clinical trial. * Prior radiation therapy within 21 days prior to start of study treatment. * Participants who have received a prior PI3K, AKT, mTORC1/2, or dual PI3K/mTOR inhibitor. * Strong CYP3A4 inhibitors, strong CYP1A2 inhibitors or CYP1A2 inducers, or clinically significant CYP3A4 inducers within 7 days before the first dose of study intervention, or participants who require treatment with strong CYP3A4 inhibitors or inducers during the study. * Prolongation of QTc interval to \>480 ms. * Type 1 or Type 2 diabetes mellitus on insulin.

Inclusion Criteria: 1. Aged ≥ 18 years old. 2. Pathologically confirmed HER2-positive advanced breast cancer. HER2 positivity is defined as IHC 3+ in \>10% immunoreactive cells or HER2 gene amplification confirmed by in situ hybridization (ISH), which shall be verified by the pathology department of the participating center. 3. Patients with advanced breast cancer who have received no more than 2 lines of prior systemic therapies. 4. Expected survival time ≥ 4 months. 5. Have at least one measurable lesion per RECIST 1.1 criteria (helical CT scan lesion diameter ≥ 10 mm with slice thickness ≤ 5 mm). 6. Adequate major organ function without blood transfusion. 7. Voluntarily participate in the study, sign informed consent form, with good compliance and willingness to complete follow-up visits. Exclusion Criteria: 1. Prior treatment with anti-HER2 antibody-drug conjugates (ADC). 2. Known leptomeningeal metastasis or active brain metastasis. 3. A history of other malignancies within the past 5 years, except for cured cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma. Malignancies cured solely by surgery more than 5 years prior to enrollment are allowed. 4. Major surgery or severe trauma within 4 weeks before enrollment, or planned major surgery during the study period. 5. Participation in other investigational new drug clinical trials within 4 weeks prior to enrollment. 6. Presence of hereditary bleeding tendency or coagulation disorders. 7. Uncontrolled hypertension with systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg despite standard antihypertensive therapy. 8. A history of clinically significant pulmonary diseases, including but not limited to interstitial pneumonia, active pneumonia, pulmonary fibrosis and radiation pneumonitis (excluding asymptomatic post-radiation changes without treatment requirement). 9. A history of severe cardiac diseases or uncontrolled cardiac conditions, including NYHA class II or higher cardiac insufficiency, unstable angina, myocardial infarction within one year, and arrhythmias requiring clinical intervention. 10. Conditions affecting drug intake and absorption, such as dysphagia, chronic diarrhea and intestinal obstruction. 11. Known allergy to any component of the study drugs. 12. Uncontrolled pleural effusion or ascites that cannot be relieved by drainage or other clinical interventions. 13. Severe uncontrolled comorbidities, including immune deficiency disorders (e.g. HIV positivity, history of organ transplantation), active hepatitis B or hepatitis C, and severe ongoing infections requiring systemic anti-infective treatment. 14. Any other conditions considered inappropriate for study enrollment by the investigator.

Inclusion Criteria: 1. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder. 2. Patients aged 12-22 years with at least one guardian to monitor them for 3 months 3. HAMD-17 Total score ≥18 4. Patients who had two or more non-suicidal self-injury behaviors meeting the 5.DSM-5 diagnostic criteria in the 2 weeks before admission (NSSI behavior of more than 5 days in the past year) 6.Obtain informed consent from patients and guardians \- Exclusion Criteria: 1. Substance abusers such as psychoactive drugs or alcohol. 2. Severe physical disability and unable to complete follow-up. 3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc. 4. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime. Unable to read, understand and complete the assessment or to cooperate with the investigators. 5. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for TIS. 6. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) or TMS within 3 months before baseline. 7. Other examination abnormalities considered to be inappropriate by investigators. \-

Inclusion Criteria: Cluster level (primary care facilities): * Township health centers or community health service centers that provide routine primary care management services for both hypertension and diabetes. * Agree to participate in cluster randomization and study procedures. * Have basic capacity for chronic disease follow-up and data recording. Individual participant level (patients): * Aged 60 to 74 years. * Diagnosed with hypertension and type 2 diabetes mellitus for at least 6 months. * Received at least one chronic disease management service at the participating study site within the past 6 months. * Able to provide written informed consent. Exclusion Criteria: Cluster Level (Primary Care Facilities): * Facilities currently participating in other intervention studies or pilot programs targeting hypertension and/or diabetes management that may interfere with the study intervention. * Facilities with major organizational instability (e.g., restructuring, closure, or significant staff turnover) that would affect implementation or follow-up. Individual Level: * Severe cognitive impairment or psychiatric illness affecting participation or follow-up. * Anticipated inability to complete 6-month follow-up.

Inclusion Criteria: * Be willing and able to provide written informed consent for the trial * Be a male or female subject 18 years of age on day of signing informed consent. * Histologically proven infiltrating carcinoma of the breast on core needle biopsy that is: HER2 negative in primary tumour pre-treatment by local pathology assessed according current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines: In situ hybridization non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), OR Immunohistochemistry (IHC) 0 or IHC 1+. * Estrogen receptor (ER) and progesterone receptors (PR) positive in primary tumour pre-treatment defined as \>1% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment. * Planned to undergo standard of care therapy with abemaciclib and endocrine therapy, in the adjuvant or metastatic setting (Part 1) or the adjuvant setting (Part 2). * Be willing to provide mandatory stool samples at baseline and on treatment. * The Eastern Cooperative Oncology Group (ECOG) 0-2 Exclusion Criteria: * Patients who are pregnant or breast-feeding * Current use of any investigational agents * Uncontrolled Ulcerative Colitis, Crohn's Disease, Malabsorption syndrome or any disease significantly affecting gastrointestinal function * History or current evidence of any condition, therapy, lab abnormality or other circumstance that in the opinion of the investigator might expose the subject to risk by participating in the trial, confound the results of the trial, or interfere with the subject's participation for the full duration of the trial.

Inclusion Criteria: 1. Community-dwelling adults aged 55 years and older. 2. Able to communicate in Mandarin or Taiwanese and capable of understanding study instructions and participating in group discussions. 3. Able to complete study questionnaires independently or with assistance from research staff. Exclusion Criteria: 1. Individuals with severe cognitive impairment that precludes understanding study procedures or participation in group discussions. 2. Individuals with a current diagnosis of severe psychiatric disorders (e.g., schizophrenia, acute phase of bipolar disorder) that would make participation in group activities inappropriate. 3. Individuals who have participated in similar psychological or bibliotherapy-based interventions within the past 3 months.

Inclusion Criteria:(All must be met) * School-aged children aged 6 to 12 years. * Meet the diagnostic criteria for asthma according to the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2025 Edition). * Received regular inhaled asthma medications for at least 3 months, with moderate or better medication adherence (score ≥6 on the Morisky Medication Adherence Scale). * Pulmonary function test shows obstructive ventilatory dysfunction or small airway dysfunction. * The primary caregiver has good communication and literacy skills, can use smartphone applications (e.g., WeChat) proficiently, and is willing to participate in the study. * Written informed consent has been obtained from the participant and their legal guardian. Exclusion Criteria:(Any one leads to exclusion) * Children in acute asthma exacerbation. * Presence of other severe chronic diseases (e.g., congenital heart disease, neuromuscular disease, immunodeficiency disease, etc.). * Children with mental or psychological disorders who cannot cooperate. * Other conditions judged by the investigator to be unsuitable for participation in this study.